DE60209511T2 - Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten - Google Patents

Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten Download PDF

Info

Publication number
DE60209511T2
DE60209511T2 DE60209511T DE60209511T DE60209511T2 DE 60209511 T2 DE60209511 T2 DE 60209511T2 DE 60209511 T DE60209511 T DE 60209511T DE 60209511 T DE60209511 T DE 60209511T DE 60209511 T2 DE60209511 T2 DE 60209511T2
Authority
DE
Germany
Prior art keywords
xylometazoline
salt
ipratropium
composition
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209511T
Other languages
German (de)
English (en)
Other versions
DE60209511D1 (de
Inventor
Anette Hanne MOESGAARD
Lowenstein Karin CHRISTENSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Publication of DE60209511D1 publication Critical patent/DE60209511D1/de
Application granted granted Critical
Publication of DE60209511T2 publication Critical patent/DE60209511T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Cosmetics (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE60209511T 2001-09-18 2002-09-18 Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten Expired - Lifetime DE60209511T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200101356 2001-09-18
DKPA200101356 2001-09-18
PCT/IB2002/003828 WO2003024433A2 (en) 2001-09-18 2002-09-18 Compositions for treatment of common cold, comprising ipratropium and xylometazoline

Publications (2)

Publication Number Publication Date
DE60209511D1 DE60209511D1 (de) 2006-04-27
DE60209511T2 true DE60209511T2 (de) 2006-10-05

Family

ID=8160714

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209511T Expired - Lifetime DE60209511T2 (de) 2001-09-18 2002-09-18 Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten

Country Status (20)

Country Link
US (2) US7652030B2 (enExample)
EP (2) EP1661570A3 (enExample)
JP (1) JP4500045B2 (enExample)
KR (1) KR100810872B1 (enExample)
CN (1) CN1290502C (enExample)
AT (1) ATE318601T1 (enExample)
BR (1) BRPI0212586B8 (enExample)
CA (1) CA2460140C (enExample)
DE (1) DE60209511T2 (enExample)
DK (1) DK1446119T3 (enExample)
EA (1) EA008165B1 (enExample)
ES (1) ES2259098T3 (enExample)
HU (1) HU226527B1 (enExample)
MX (1) MXPA04002500A (enExample)
NO (1) NO334441B1 (enExample)
NZ (1) NZ531792A (enExample)
PL (1) PL208686B1 (enExample)
PT (1) PT1446119E (enExample)
SI (1) SI1446119T1 (enExample)
WO (1) WO2003024433A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE60209511T2 (de) * 2001-09-18 2006-10-05 Nycomed Danmark Aps Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
WO2005084330A2 (en) * 2004-03-02 2005-09-15 Synergia Pharma, Inc. Compositions and methods for treating nasal congestion
DE102004049008A1 (de) * 2004-10-05 2006-04-06 Merck Patent Gmbh Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur
CA2592605C (en) * 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
DE102006023770A1 (de) * 2006-05-20 2007-11-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treibgasfreie Aerosolformulierung für die Inhalation
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US20090270472A1 (en) * 2008-04-25 2009-10-29 Kenneth Gould Method to use oxymetazoline to interrupt the development of the common cold syndrome
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
MX2012005961A (es) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizador.
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2978407B1 (en) * 2013-03-29 2020-05-06 Santa Farma Ilaç Sanayi A.S. Aqueous solution composition containing ipratropium and oxymetazoline
WO2014158118A1 (en) * 2013-03-29 2014-10-02 Santa Farma İlaç Sanayi̇ A.Ş. Suspension composition containing ipratropium and oxymetazoline
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
WO2015054359A1 (en) * 2013-10-08 2015-04-16 Ebadi Mark A Methods and compositions for symptomatic reflief of the common cold
HUE058904T2 (hu) 2014-05-07 2022-09-28 Boehringer Ingelheim Int Porlasztókészülék
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
CA2948071C (en) 2014-05-07 2022-08-30 Boehringer Ingelheim International Gmbh Container, nebulizer and use
EP3236933B1 (en) 2014-12-24 2018-11-14 JADRAN - GALENSKI LABORATORIJ d.d. A nasal composition containing sea water as stability-improving excipient
MX383771B (es) 2015-12-02 2025-03-14 Pablo Cortes Borrego Combinación de oximetazolina e ipratropio en aplicación tópica nasal para el tratamiento de la tos.
US20220031739A1 (en) * 2020-07-31 2022-02-03 Eye Therapies Llc Anti-viral compositions and methods of use thereof
CN121868276A (zh) * 2022-10-25 2026-04-17 广东药科大学 托品酸及其衍生物在制备免疫与炎症相关疾病治疗药物中的医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137981T3 (es) * 1991-11-19 2000-01-01 Univ Virginia Tratamiento combinado por agentes antimediaticos y antiviricos de resfriados comunes.
IL101056A (en) 1992-02-24 1997-03-18 Res & Dev Co Ltd Composition for nasal treatment
GB9218834D0 (en) 1992-09-05 1992-10-21 Procter & Gamble Nasal spray products
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
EP0780127A1 (en) 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
IL131492A0 (en) * 1997-04-30 2001-01-28 Warner Lambert Co Topical nasal antiinflammatory compositions
WO1999038492A1 (en) * 1998-01-30 1999-08-05 Novartis Consumer Health S.A. Nasal solutions
ATE253896T1 (de) 1998-06-18 2003-11-15 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
CZ295595B6 (cs) * 1999-06-22 2005-08-17 Boehringer Ingelheim International Gmbh Stálý roztok xylometazolinu a oxymetazolinu
DE60209511T2 (de) * 2001-09-18 2006-10-05 Nycomed Danmark Aps Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten

Also Published As

Publication number Publication date
NZ531792A (en) 2006-02-24
HU226527B1 (hu) 2009-03-30
EP1446119B1 (en) 2006-03-01
CN1555263A (zh) 2004-12-15
ATE318601T1 (de) 2006-03-15
EA200400444A1 (ru) 2005-02-24
HUP0402075A2 (hu) 2005-02-28
US8450339B2 (en) 2013-05-28
ES2259098T3 (es) 2006-09-16
DE60209511D1 (de) 2006-04-27
KR100810872B1 (ko) 2008-03-06
PL370536A1 (en) 2005-05-30
JP2005505569A (ja) 2005-02-24
US20100093783A1 (en) 2010-04-15
WO2003024433A2 (en) 2003-03-27
EP1661570A2 (en) 2006-05-31
EA008165B1 (ru) 2007-04-27
HUP0402075A3 (en) 2008-04-28
US20040248924A1 (en) 2004-12-09
WO2003024433A3 (en) 2004-06-10
BRPI0212586B8 (pt) 2021-05-25
DK1446119T3 (da) 2006-07-10
KR20040049849A (ko) 2004-06-12
EP1661570A3 (en) 2012-10-24
US7652030B2 (en) 2010-01-26
NO20041070L (no) 2004-05-18
CN1290502C (zh) 2006-12-20
HK1067984A1 (en) 2005-04-22
EP1446119A2 (en) 2004-08-18
PT1446119E (pt) 2006-07-31
PL208686B1 (pl) 2011-05-31
CA2460140A1 (en) 2003-03-27
CA2460140C (en) 2009-09-01
BR0212586B1 (pt) 2013-11-19
NO334441B1 (no) 2014-03-03
BR0212586A (pt) 2004-10-13
MXPA04002500A (es) 2004-11-22
JP4500045B2 (ja) 2010-07-14
SI1446119T1 (sl) 2006-08-31

Similar Documents

Publication Publication Date Title
US8450339B2 (en) Compositions for treatment of common cold
DE69024672T2 (de) Sprays zur Behandlung von Infektionen des Tractus Respiratorius
DE60133203T3 (de) Fentanyl Zusammensetzung für nasale Anwendung
DE69108200T2 (de) 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1).
AT16553U1 (de) Intranasale pharmazeutische Darreichungsformen umfassend Naloxon
WO2001060407A2 (de) Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis
EP0125634A1 (de) Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens
DE69411726T2 (de) Zusammensetzungen zur freigabe einer aromatischen substanz in die nase
EP2200603B1 (de) Osmolyte zur behandlung von allergisch bedingten atemwegserkrankungen
DE69928806T2 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
EP2050435B1 (de) Hustenpräparat
DE19519056A1 (de) Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation
CH662734A5 (de) Antischnarchmittel.
EP0240907B1 (de) Verwendung von trans-4-[(2-Amino-3,5-dibrom-benzyl)-amino]cyclohexanol
DE60023341T2 (de) Orale lösung enthaltend galanthamine und ein süssungsmittel
DE60220825T2 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EP2818167A1 (de) Antiviral wirksame pharmazeutische Zusammensetzung
EP4349333B1 (de) Verwendung von aminopyridin, insbesondere amifampridin, bei der behandlung einer viral assoziierten fatigue
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
AU2002329578B2 (en) Compositions for treatment of common cold
AU2002329578A1 (en) Compositions for treatment of common cold
HK1067984B (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold
HK1092064A (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold

Legal Events

Date Code Title Description
8364 No opposition during term of opposition